Small Intestinal Bacterial Overgrowth and Orocecal Transit Time in Patients of Inflammatory Bowel Disease

2013 ◽  
Vol 58 (9) ◽  
pp. 2594-2598 ◽  
Author(s):  
S. V. Rana ◽  
S. Sharma ◽  
A. Malik ◽  
J. Kaur ◽  
K. K. Prasad ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Transit Time ◽  
Bowel Disease ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Orocecal Transit Time ◽  
Intestinal Bacterial Overgrowth ◽  
Orocecal Transit ◽  
Inflammatory Bowel ◽  
Small Intestinal

Mo1907 Small Intestinal Bacterial Overgrowth in Inflammatory Bowel Disease

2016 ◽  
Vol 150 (4) ◽  
pp. S813
Author(s):  
Shirley Cohen-Mekelburg ◽  
Zaid Tafesh ◽  
Elliot Coburn ◽  
Russell Weg ◽  
Neena Malik ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Intestinal Bacterial Overgrowth ◽  
Inflammatory Bowel ◽  
Small Intestinal

scholarly journals Evidence of Prolonged Orocecal Transit Time and Small Intestinal Bacterial Overgrowth in Acromegalic Patients

2007 ◽  
Vol 92 (6) ◽  
pp. 2119-2124 ◽  
Author(s):  
Eugenia Resmini ◽  
Andrea Parodi ◽  
Vincenzo Savarino ◽  
Alfredo Greco ◽  
Alberto Rebora ◽  
...  
Keyword(s):  
Disease Control ◽  
Transit Time ◽  
Somatostatin Analogs ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Hydrogen Breath Test ◽  
Orocecal Transit Time ◽  
Intestinal Bacterial Overgrowth ◽  
Orocecal Transit ◽  
Small Intestinal

Abstract Context: Gastrointestinal abnormalities in acromegaly include dolichomegacolon, slow colonic transit, and increased prevalence of colonic polyps. Conversely, no data are available on the small intestine. Objective: The aim of the study was to investigate the orocecal transit time (OCTT) and the presence of small intestinal bacterial overgrowth (SIBO). Patients: A total of 41 acromegalic patients and 30 sex- and age-matched control subjects entered the study. Acromegalic patients were classified according to the medical treatment with somatostatin analogs as “treated” (n = 22) and “untreated” (n = 19), whereas according to the disease control, as “controlled” (n = 17), “uncontrolled” (n = 10), and “partially controlled” (n = 14). Patients and controls completed a questionnaire and underwent a standardized 10-g lactulose hydrogen breath test to determine the OCTT and presence of SIBO. SIBO-positive patients underwent eradication with rifaximine. Results: An increased prevalence of SIBO (18 of 41 vs. 1 of 30; P < 0.0001) and a significantly delayed OCTT (169.53 ± 8.15 vs. 107.25 ± 6.56 min; P < 0.0001) were evidenced in patients compared with controls. No significant statistical differences were found between “treated” or “untreated” patients positive for SIBO or between “controlled,” “partially controlled,” and “uncontrolled” patients. OCTT was significantly delayed in “treated” vs. “untreated” patients (183.21 ± 9.01 and 158.89 ± 6.38, respectively; P = 0.02) and in patients compared with controls (105.75 ± 6.34; P < 0.0001). Rifaximine eradicated SIBO in more than 50% of patients who underwent treatment. Conclusions: These data demonstrate for the first time that SIBO occurs more frequently in acromegalic patients, however, it can be successfully treated by a specific antibiotic. Medical therapy with somatostatin analogs does not affect SIBO prevalence. OCTT resulted significantly prolonged in both “treated” and “untreated” patients, suggesting that acromegaly determines per se an impairment of the intestinal motility. Indeed, disease control seems irrelevant on the delayed OCTT, suggesting that this alteration might be an irreversible complication of acromegaly, probably related to an autonomic intestinal disorder, as we have previously demonstrated at the cardiac level.

scholarly journals Prevalence of small intestinal bacterial overgrowth syndrome among patients with inflammatory bowel disease and its impact on nutritional status and clinical manifestations

2021 ◽  
Vol 55 (3) ◽  
pp. 166-171
Author(s):  
Yu.M. Stepanov ◽  
M.V. Titova ◽  
N.V. Nedzvetska
Keyword(s):  
Inflammatory Bowel Disease ◽  
Nutritional Status ◽  
Bowel Disease ◽  
Total Protein ◽  
Clinical Manifestations ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
Intestinal Bacterial Overgrowth ◽  
Inflammatory Bowel ◽  
Small Intestinal

Background. In recent years, there has been high interest in the prevalence of small intestinal bacterial overgrowth (SIBO) syndrome in various populations. Chronic inflammatory bowel disease (IBD) is known to be a heterogeneous group of disorders, with a high degree of geographical variability in terms of symptoms, nature of progression, clinical manifestations, or combination with other types of pathologies. Since the involvement of the intestinal microbiome plays an important role in the etiopathogenesis of inflammatory bowel disease, the combination of SIBO and IBD is increasingly being considered and studied recently. Since the symptoms of both pathological conditions are significantly echoed, and therefore exacerbated by the combination, the manifestations of malnutrition become more pronounced, which negatively affects the nutritional status of patients with IBD. The purpose of the study is to determine the frequency of SIBO in patients with IBD depending on the nosological forms and to investigate its effect on clinical and laboratory indicators of nutritional status and clinical manifestations. Materials and methods. We examined 100 patients with IBD, aged 19 to 79 years, on average (42.54 ± 1.50) years, including 70 patients with ulcerative colitis (UC), and 30 — with Crohn’s disease (CD). All patients underwent general clinical examination, anthropometric measurements, general and biochemical blood tests (with the determination of total protein, albumin, prealbumin). To characterize the state of the small intestine microbiota (presence of SIBO), all patients underwent a hydrogen breath test with glucose loading using a Gastro+ Gastrolyzer gas analyzer from Bedfont Scientific Ltd (UK). Results. The analysis of SIBO frequency showed the changes in the state of the small intestinal microflora in 45 % of patients with IBD. The prevalence of SIBO was higher in the group of patients with CD — 53.3 % (16) than in the group with UC — 41.4 % (29). The presence of SIBO in the group of patients with UC had statistical significance and a direct correlation with the duration of the disease — (9.3 ± 6.2) versus (2.9 ± 3.1) years (p = 0.001, r = 0.55). There was a decrease in weight and body mass index (BMI) in patients with SIBO, especially in patients with Crohn’s disease, and accounted for (19.8 ± 3.5) kg/m2. There was a significant difference between the levels of total protein in patients with SIBO and without it, both in the basic group and in the group of UC: (65.8 ± 8.4) vs. (70.2 ± 8.2) g/l (p = 0.009, r = –0.232) and (66.5 ± 8.3) vs. (70.7 ± 7.4) g/l (p = 0.029), respectively, and albumin levels were reduced in both nosological groups. No relationship was found between the severity of abdominal pain and the presence of SIBO. When SIBO was detected, the manifestations of flatulence significantly prevailed in patients with UC — 75.8 % (n = 22), and diarrheal syndrome in patients with CD — 75 % (n = 12). Conclusions. The obtained results indicate a high prevalence of SIBO in patients with IBD. Patients with CD suffered from SIBO more often (53.3 %) than patients with UC (41.4 %) (with a predominance of patients with severe disease). A direct correlation of SIBO with the disease duration in patients with UC (r = 0.55, р < 0.05) was revealed, which is explained by the violation of physiological barriers that prevent the emergence of SIBO, due to more episodes of exacerbation, long-term use of drugs and concomitant pathology with time. The negative impact of SIBO on nutritional status manifested in weight loss, reduced BMI and other anthropometric (mid-upper arm circumference, mid-arm muscle circumference, triceps skinfold) and laboratory (total protein, albumin, prealbumin) parameters in these patients. The most common symptoms in patients with IBD with SIBO were abdominal pain, diarrhea, and flatulence that reflected the typical clinical picture of SIBO.

Orocecal Transit Time and Small Intestinal Bacterial Overgrowth in Type 2 Diabetes Patients from North India

2011 ◽  
Vol 13 (11) ◽  
pp. 1115-1120 ◽  
Author(s):  
Satyavati Rana ◽  
Anil Bhansali ◽  
Sanjay Bhadada ◽  
Surendra Sharma ◽  
Jaspreet Kaur ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Transit Time ◽  
Bacterial Overgrowth ◽  
Small Intestinal Bacterial Overgrowth ◽  
North India ◽  
Orocecal Transit Time ◽  
Intestinal Bacterial Overgrowth ◽  
Orocecal Transit ◽  
Small Intestinal
Sign in / Sign up

Export Citation Format

Share Document